【作者】 王玲；

【导师】 侯建青；

【作者基本信息】 青岛大学 ， 妇产科学（专业学位）， 2019， 硕士

【摘要】 目的:探讨SHIP2在上皮性源性卵巢癌中的表达及其与临床病理学特征之间的关系。实验材料与方法:收取于2012年01月份至2018年06月份在青岛大学附属烟台毓璜顶医院妇科医疗区住院治疗,并以手术治疗为初次治疗方案的卵巢组织(卵巢良性组织、上皮源性恶性肿瘤组织各100例)的石蜡切块,用免疫组织化学技术(IHC)检测这些组织中SHIP2所表达的蛋白质的位置及强度;收集2016年12月份至2018年06月份的新鲜卵巢组织标本(卵巢良性组织及卵巢上皮源性恶性肿瘤各30例),用RT-PCR技术评估SHIP2 m RNA在卵巢上皮性源性恶性肿瘤及良性病变中的表达差异;以及SHIP2蛋白、m RNA表达情况与上皮性源性卵巢癌临床病理学特征之间的关系。结果:(1)通过免疫组化方法检测到SHIP2在卵巢上皮源性恶性肿瘤组织中的阳性表达率为68%,明显高于良性病变组织21%的阳性表达率,表达差异具有统计学意义(P<0.001),且其表达主要位于胞浆中。SHIP2表达程度与FIGO标准分期、分化程度、淋巴结转移之间存在显著相关,P值分别是0.001、0.010、0.00。但与年龄无明显关系,P=0.748。(3)通过RT-PCR检测到SHIP2 m RNA在卵巢上皮源性恶性肿瘤中的相对表达量为卵巢良性病变组织的2.479倍,P=0.008,表达差异具有统计学意义,且SHIP2 m RNA在晚期、分化差、有淋巴结转移时的相对表达量分别为早期组、高分化组、无淋巴结转移组的3.107倍、2.164倍、1.687倍,P分别为:0.004、0.022、0.028,差异具有统计意义,但在不同年龄分组中,低龄组SHIP2 m RNA相对表达量为高龄组的0.656倍,P=0.054,表达无差异。结论:(1)SHIP2 m RNA、蛋白在上皮源性卵巢恶性组织中表达明显高于卵巢良性病变组织,由此推断SHIP2在上皮源性卵巢癌在发病中可能起重要作用。(2)SHIP2 m RNA、蛋白高表达的患者其分期晚、分级高、淋巴结转移率高,这均说明了SHIP2可能在上皮源性卵巢癌的发生及疾病进展中存在重要作用,SHIP2也许会成为早期发现、诊断卵巢上皮源性恶性肿瘤、判断其预后、评估治疗效果的有效的生物学分子之一。更多还原

【Abstract】 Objective: To investigate the expression of SHIP2 in epithelial ovarian cancer and its relationship with clinicopathological features。Materials and Methods: From January 2012 to June 2018,paraffin sections of ovarian tissues(100 cases of benign ovarian tissues and 100 cases of epithelial malignant tumors)were selected from gynecological department of Yuhuangding Hospital,Yantai,affiliated to Qingdao University.Immunohistochemical technique(IHC)was used to detect the location and intensity of SHIP2 protein expression in these tissues.Fresh ovarian tissue specimens(30 benign ovarian tissues and 30 epithelial ovarian malignant tumors)from December 2016 to June 2018 were collected.,the expression of SHIP2 in epithelial ovarian malignant tumors and benign ovarian lesions was assessed by RT-PCR,and the relationship between the expression of SHIP2 protein and gene and the clinicopathological characteristics of epithelial ovarian cancer was discussed.Result:(1)The positive expression rate of SHIP2 in epithelial ovarian malignant tumors was68% by immunohistochemical method,which was significantly higher than that in benign ovarian lesions(21%).The difference was statistically significant(P < 0.001),and the expression of SHIP2 was mainly in the cytoplasm.The expression of SHIP2 was significantly correlated with FIGO staging,differentiation and lymph node metastasis,with P values of 0.001,0.010 and 0.00,respectively.But there was no significant correlation with age,P=0.748.(2)The relative expression of SHIP2 in epithelial malignant ovarian tumors was2.479 times higher than that in benign ovarian lesions(P=0.008)detected by RT-PCR.The relative expression of SHIP2 in advanced,poorly differentiated and lymph node metastasis groups was 3.107,2.164 and 1.687 times higher than that in early,highly differentiated and non-lymph node metastasis groups,respectively,P=0.008.The expression of SHIP2 was 0.004,0.022 and 0.028 in different age groups,but the relative expression of SHIP2 in the younger group was 0.656 times higher than that in the older group,and P= 0.054.There was no difference in the expression of SHIP2 in the younger group.Conclusion:(1)The expression of SHIP2 in epithelial ovarian malignant tissues was significantly higher than that in benign ovarian lesions,which suggested that SHIP2 might play an important role in the pathogenesis of epithelial ovarian cancer.(2)SHIP2 may play an important role in the occurrence and progression of epithelial ovarian cancer.SHIP2 may become an effective biological molecule for early detection,diagnosis,prognosis and treatment of epithelial ovarian cancer.更多还原